Research programme: retinitis pigmentosa therapeutics - Asklepios

Drug Profile

Research programme: retinitis pigmentosa therapeutics - Asklepios

Alternative Names: BNP-RP

Latest Information Update: 16 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asklepios BioPharmaceutical
  • Developer Asklepios BioPharmaceutical; ForSight VISION4
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Retinitis pigmentosa

Most Recent Events

  • 10 Jan 2017 ForSight VISION4 has been acquired by and merged into Roche
  • 16 Jul 2016 No recent reports of development identified for research development in Retinitis-pigmentosa in USA (Parenteral)
  • 25 Sep 2012 Early research in Retinitis pigmentosa in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top